Equity · Healthcare
TRVI
NASDAQTrevi Therapeutics (TRVI)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 2.7B USD
- EPS, diluted, year to Dec 2025
- −0.32 USD
- 52-week range
- 6.40 USD – 19.50 USD
- Avg volume
- 583.0K
as of Jul 17, 2026
Have Trevi Therapeutics (TRVI) insiders bought or sold shares recently?
In the 90 days to 12 Nov 2026, Trevi Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Dec 2025, show no open-market purchase.
Form 4, 90 days to 12 Nov 2026, newest reported trade 15 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Sep 2026 | Heffernan Michael ThomasDirector | Sell | 39,473 | 596K USD |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Sep 2026 | Heffernan Michael ThomasDirector | Option exercise | 39,473 | 126K USD |
Which funds hold Trevi Therapeutics (TRVI)?
5 of the 45 institutional funds we track reported a Trevi Therapeutics position for the quarter ended 30 Jun 2026 — a combined 101.1M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Marshall Wace | Trimmed | 2,674,137 | 49.9M USD | −32.6% |
| Viking Global Investors | Trimmed | 1,544,644 | 28.8M USD | −51.7% |
| Balyasny Asset Management | Added | 845,087 | 15.8M USD | +78.3% |
| D. E. Shaw & Co. | Added | 281,996 | 5.3M USD | +55.5% |
| Tudor Investment Corp | Held (±25%) | 73,978 | 1.4M USD | +14.7% |
| AQR Capital Management | Exited | |||
| Citadel Advisors | Exited | |||
| Millennium Management | Exited | |||
| Two Sigma Investments | Exited |
What has been filed or recorded for Trevi Therapeutics (TRVI)?
The filings we hold for Trevi Therapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.13 USD | |
| 30 Sep 2026 | Financials | Total assets | 310.8M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 302.8M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.11 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.09 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.32 USD | |
| 31 Dec 2025 | Financials | Net income | −42.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.32 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.08 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.09 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.09 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.47 USD |
What do people ask about Trevi Therapeutics (TRVI)?
What is Trevi Therapeutics’ market cap?2.7B
Trevi Therapeutics is worth 2.7B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
Have Trevi Therapeutics insiders bought or sold shares recently?1 sale
In the 90 days to 12 Nov 2026, Trevi Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 2 Dec 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Trevi Therapeutics?5 of 45
5 of the 45 funds we track reported a Trevi Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Marshall Wace, Viking Global Investors and Balyasny Asset Management. See Funds
When did Trevi Therapeutics last report earnings?−0.13
Trevi Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.13 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings